FRFernando Faglioni Ribas

Fernando Faglioni Ribas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fernando Faglioni Ribas has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Off-Pump Versus On-Pump Coronary Artery Bypass Grafting in Prefrail and Frail Patients: 30-Day and 1-Year Outcomes From the FRAGILE Randomized Trial

    by Omar Asdrúbal Vilca Mejia, Bianca Meneghini, Fabiane Letícia de Freitas, Maurilio Onofre Deininger, Rodrigo Coelho Segalote, Felipe Cosentino, Alexandre Ciappina Hueb, Mauricio Landulfo Jorge Guerrieri, Fernando Faglioni Ribas, Fabiano Gonçalves Jucá, et al.

    BACKGROUND: Frailty is associated with worse outcomes after coronary artery bypass grafting (CABG). However, the comparative effectiveness of off-pump CABG (OPCAB) versus on-pump CABG (ONCAB) in prefrail and frail patients remains uncertain. METHODS: This multicenter, randomized, open-label trial enrolled patients ≥60 years of age classified as prefrail or frail, randomized 1:1, between January 2018 and December 2024. The primary outcome was a 30-day composite of death, myocardial infarction, stroke, renal failure, acute respiratory distress syndrome, or reoperation for bleeding. Secondary outcomes included ventilation time, intensive care unit and hospital stay, transfusion requirements, completeness of revascularization, surgical wound infection at 30 days, and neurocognitive function preoperatively and at 1 year. Analyses followed the intention-to-treat principle; relative risks with 95% CIs were estimated. RESULTS: A total of 508 patients were included (OPCAB, n=258; ONCAB, n=250; median age, 68 years [interquartile range, 65.0–73]; 30.5% female). The primary composite outcome occurred in 28 patients receiving OPCAB (10.9%) and 40 patients receiving ONCAB (16.0%; relative risk, 1.47 [95% CI, 0.94–2.31]; P =0.09). Surgical wound infection was more frequent with ONCAB (20 [8.0%] versus 9 [3.5%]; P =0.04). No significant differences were observed in neurocognitive or quality of life outcomes at 1 year. Estimated 1-year survival probabilities were 96.1% and 92.8% in the OPCAB and ONCAB groups, respectively ( P =0.099). CONCLUSIONS: In prefrail and frail patients undergoing CABG, OPCAB and ONCAB resulted in similar rates of the primary composite outcome. No significant differences between OPCAB and ONCAB were found in neurocognitive outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02338947.

  • Open Access

    Torsades de pointes and myocardial infarction following reversal of supraventricular tachycardia with adenosine: a case report

    by Milena Ribeiro Paixão, Fernando Faglioni Ribas, Tarso Augusto Duenhas Accorsi, Karine De Amicis, José Leão de Souza

    Adenosine is an antiarrhythmic drug that slows conduction through the atrioventricular node and acts as a coronary blood vessel dilator. This case report highlights two unusual life-threatening events following the use of adenosine to revert supraventricular tachycardia in a structurally normal heart: non-sustained polymorphic ventricular tachycardia and myocardial infarction. A 46-year-old woman presented to the emergency department with a two-hour history of palpitations and was diagnosed with supraventricular tachycardia. Vagal maneuvers were ineffective, and after intravenous adenosine administration, the


  • Open Access

    Papel do edema miocárdico após procedimentos de revascularização avaliado por ressonância magnética cardíaca

    by Fernando Faglioni Ribas

    Introdução: Evidências sugerem que o edema miocárdico (EM), observado à ressonância magnética por meio do aumento da intensidade do sinal em sequencias ponderadas em T2, representa uma forma de injúria...

  • Open Access

    Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease

    by Paulo Cury Rezende, Mark Andrew Hlatky, Whady Hueb, Rosa Maria Rahmi Garcia, Luciano da Silva Selistre, Eduardo Gomes Lima, Cibele Larrosa Garzillo, Thiago Luis Scudeler, Gustavo Andre Boeing Boros, Fernando Faglioni Ribas, et al.

    Glucose control among patients with diabetes is primarily guided by the periodic assessment of glycated hemoglobin (HbA1c) levels. Strict control of diabetes, indicated by lower HbA1c levels, has been associated with reduced microvascular complications, including nephropathy, retinopathy, and peripheral neuropathy.1-3 Strict control of diabetes is less associated with macrovascular events, such as myocardial infarction (MI) or ischemic stroke. Although some studies4 have shown that lower HbA1c levels were associated with lower rates of cardiovascular mortality and MI, landmark randomized clinical trials5,6 have not found significant decreases in cardiovascular end points with intensive glucose control. Additionally, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial7 was prematurely halted because of higher rates of cardiac mortality in the group of patients with target HbA1c levels lower than 6.0% (to convert to proportion of total hemoglobin, multiply by 0.01).7